Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Ovarian Cancer Metastatic × Interleukin-2 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 93 Carcinoma, Renal Cell 33 Neoplasm Metastasis 30 Leukemia, Myeloid, Acute 28 Breast Neoplasms 22 Neoplasms 20 Lymphoma, Non-Hodgkin 19 Leukemia 18 Kidney Neoplasms 17 Carcinoma, Non-Small-Cell Lung 16 Skin Neoplasms 15 Ovarian Neoplasms 15 Neuroblastoma 15 Recurrence 13 Lymphoma 13 Colorectal Neoplasms 13 Leukemia, Lymphocytic, Chronic, B-Cell 12 Myelodysplastic Syndromes 9 Uveal Melanoma 8 Uterine Cervical Neoplasms 8 Precursor Cell Lymphoblastic Leukemia-Lymphoma 8 Lymphoma, Follicular 8 Multiple Myeloma 7 Head and Neck Neoplasms 7 Triple Negative Breast Neoplasms 6 Stomach Neoplasms 6 Squamous Cell Carcinoma of Head and Neck 6 Lymphoma, Large B-Cell, Diffuse 6 Lung Neoplasms 6 Hodgkin Disease 6

Interventions

fludarabine 1 aldesleukin 1 Interleukin-2 1 Cyclophosphamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04389229 2020-12-16

OVSTAR

Immetacyte Ltd

Phase 1/2 Withdrawn

Ovarian Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡